Esomeprazole Capsules (Reformulation)

Esomeprazole Capsules (Reformulation)
Product Description

A gastro-resistant capsule reformulation associated with gastroesophageal reflux disease.

Dosage form: Gastro-resistant capsule Strengths: 20 mg and 40 mg Therapeutic area: Alimentary tract and metabolism Key indication: Gastroesophageal reflux disease Product class: Peptic ulcer and gastro-oesophageal disease treatment Expected dossier availability: Q4 2026 Estimated CPP timing: Q3 2028 This capsule reformulation should be clearly differentiated from the commercially available Esomeprazole gastro-resistant tablet.

Medis ehf.

  • Country/Region:
    Iceland
  • On CPHI since:
    2015
  • Certificates:
    2
  • Employees:
    100 - 249
Company types
Licensee
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Out-licensing specialist
Specifications
  • Details
    A gastro-resistant capsule reformulation associated with gastroesophageal reflux disease.

    Dosage form: Gastro-resistant capsule Strengths: 20 mg and 40 mg Therapeutic area: Alimentary tract and metabolism Key indication: Gastroesophageal reflux disease Product class: Peptic ulcer and gastro-oesophageal disease treatment Expected dossier availability: Q4 2026 Estimated CPP timing: Q3 2028 This capsule reformulation should be clearly differentiated from the commercially available Esomeprazole gastro-resistant tablet.

Medis ehf.

  • Country/Region:
    Iceland
  • On CPHI since:
    2015
  • Certificates:
    2
  • Employees:
    100 - 249
Company types
Licensee
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Out-licensing specialist

More Products from Medis ehf. (26)

  • Dabrafenib (Pipeline)

    Product Dabrafenib (Pipeline)

    A targeted-oncology pipeline opportunity associated with metastatic melanoma and non-small-cell lung cancer.

    Dosage form: Hard capsule Strengths: 50 mg and 75 mg Therapeutic area: Antineoplastic and immunomodulating agents Key indications: Metastatic melanom...
  • Dapagliflozin (Pipeline)

    Product Dapagliflozin (Pipeline)

    A single-agent oral pipeline opportunity associated with type 2 diabetes mellitus.

    Dosage form: Film-coated tablet Strengths: 5 mg and 10 mg Therapeutic area: Alimentary tract and metabolism Key indication: Type 2 diabetes mellitus Product class: Blo...
  • Dapagliflozin / Metformin (Pipeline)

    Product Dapagliflozin / Metformin (Pipeline)

    A fixed-dose combination pipeline opportunity associated with type 2 diabetes mellitus.

    Dosage form: Film-coated tablet Strengths: 5 mg/850 mg and 5 mg/1000 mg Therapeutic area: Alimentary tract and metabolism Key indication: Type 2 diabetes mellitus Produ...
  • Eltrombopag (Commercial)

    Product Eltrombopag (Commercial)

    A focused oral hematology opportunity associated with the management of thrombocytopenia.

    Dosage form: Film-coated tablet Strengths: 25 mg, 50 mg and 75 mg Therapeutic area: Blood and blood-forming organs Key indication: Thrombocytopenia Product class: ...
  • Empagliflozin (Pipeline)

    Product Empagliflozin (Pipeline)

    A two-strength oral pipeline opportunity associated with type 2 diabetes mellitus.

    Dosage form: Film-coated tablet Strengths: 10 mg and 25 mg Therapeutic area: Alimentary tract and metabolism Key indication: Type 2 diabetes mellitus Product class: Bl...
  • Enzalutamide (Pipeline)

    Product Enzalutamide (Pipeline)

    An oral oncology pipeline opportunity associated with prostate cancer.

    Dosage form: Film-coated tablet Strengths: 40 mg and 80 mg Therapeutic area: Antineoplastic and immunomodulating agents Key indication: Prostate cancer Product class: Endocrine th...
  • Esomeprazole Tablets (Commercial)

    Product Esomeprazole Tablets (Commercial)

    An established gastroenterology opportunity available in two widely recognised strengths.

    Dosage form: Gastro-resistant tablet Strengths: 20 mg and 40 mg Therapeutic area: Alimentary tract and metabolism Key indications: Duodenal and gastric ulcers, erosive esophagitis, gastroesophageal reflux d...
  • Ferric Carboxymaltose (Commercial)

    Product Ferric Carboxymaltose (Commercial)

    An intravenous product opportunity for partners active in hospital care, hematology and iron-deficiency management.

    Dosage form: Solution for injection or infusion Strength: 50 mg/ml Therapeutic area: Blood and blood-forming organs Key indication: Iron-deficiency ...
  • Filgrastim (Commercial)

    Product Filgrastim (Commercial)

    A pre-filled syringe opportunity associated with supportive care and the management of neutropenia.

    Dosage form: Solution for injection in a pre-filled syringe Strengths: 30 MIU/0.5 ml and 48 MIU/0.8 ml Therapeutic area: Antineoplastic and immunomodulating agents ...
  • Levodropropizine Oral Liquid (Commercial)

    Product Levodropropizine Oral Liquid (Commercial)

    A complementary liquid presentation associated with the symptomatic relief of dry cough.

    Dosage form: Oral liquid Strength: 6 mg/ml Therapeutic area: Respiratory system Key indication: Symptomatic relief of dry cough Product class: Cough suppressant Dossier st...
  • Levodropropizine Tablets (Commercial)

    Product Levodropropizine Tablets (Commercial)

    An oral solid presentation associated with the symptomatic relief of dry cough.

    Dosage form: Tablet Strength: 60 mg Therapeutic area: Respiratory system Key indication: Symptomatic relief of dry cough Product class: Cough suppressant Dossier status: Available ...
  • Lisdexamfetamine (Commercial)

    Product Lisdexamfetamine (Commercial)

    A broad-strength capsule opportunity associated with attention deficit hyperactivity disorder.

    Dosage form: Hard capsule Strengths: 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg Therapeutic area: Nervous system Key indication: Attention deficit hyperactivity disorde...

Medis ehf. resources (2)